The CTN 222 Research Network

Community Partnerships

The Canadian Co-infection Cohort is proud to partner with both local and national community organizations. Our collaborators include CATIE, AIDS Community Care Montreal (ACCM), and the “Coalition des organismes communautaires Québécois de lutte contre le sida” (COCQ-SIDA).

Established in 1990, CATIE’s mandate has expanded to providing both treatment and prevention information on HIV and hepatitis C to frontline service providers across Canada. CATIE strengthens Canada’s response to HIV and hepatitis C by bridging research and practice. They connect healthcare and community-based service providers with the latest science and promote good practices for prevention and treatment programs.

Established in 1987, ACCM is a volunteer-driven community organization that provides support services and treatment information to people living with HIV/AIDS and/or hepatitis C. The voices of their members are central to ACCM’s guidance, and they work in collaboration with their many communities to build a compassionate and caring response to HIV and hepatitis C.

Established in 1990, the COCQ-SIDA’s mission is to bring together Quebec community organizations involved in the fight against HIV/AIDS and exercise its leadership in order to encourage, support, consolidate, and promote autonomous community action in the fight against HIV/AIDS in the Quebec territory.

International Collaborations

The Canadian Co-infection Cohort is proud to be included in two international cohorts: InCHEHC and Hep-CAUSAL.

The Burnet Institute’s International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHECH) pools data from 15 observational cohorts from Australia, France, Spain, Switzerland, the Netherlands, Georgia, the United States, and Canada. It is the largest international cohort of people living with HIV with well-characterized data on HCV co-infection.

Pooling data from approximately 75,000 participants, the aim of this sizeable cohort is to measure and identify correlates of rare outcomes that cannot be analyzed within individual cohorts or countries, such as HCV reinfection after successful treatment, treatment failure, and liver-related mortality.

InCHEHC also allows for the interim assessment of the WHO elimination targets in 2020-2022, facilitating refinement of policy and practice within the target period.

Harvard’s School of Public Health’s Hep-CAUSAL is a consortium of cohorts of people who are co-infected with HIV and HCV in Europe and the Americas. By combining observational data and causal inference methods, Hep-CAUSAL estimates the long-term risk of HCV reinfection, hepatic disease, and extra-hepatic disease for all co-infected people. The findings are set to inform post-cure management guidelines and how to maximize the benefits of DAA treatment in the long term.